280 results on '"Beauregard, Jean-Mathieu"'
Search Results
2. Deep transformer-based personalized dosimetry from SPECT/CT images: a hybrid approach for [177Lu]Lu-DOTATATE radiopharmaceutical therapy
3. Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.
4. A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
5. Role of AI in Theranostics: Towards Routine Personalized Radiopharmaceutical Therapies
6. Tau positron emission tomography, cerebrospinal fluid and plasma biomarkers of neurodegeneration, and neurocognitive testing: an exploratory study of participants with myotonic dystrophy type 1
7. Impact of the dead-time correction method on quantitative 177Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy
8. Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer
9. Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours.
10. Differential Detection of Hepatic Metastases on 68Ga-DOTATATE PET/CT and 177Lu-DOTATATE SPECT/CT
11. Role of Artificial Intelligence in Theranostics: Toward Routine Personalized Radiopharmaceutical Therapies
12. Harmonization of nomenclature for molecular imaging metrics of tumour burden: molecular tumour volume (MTV), total lesion activity (TLA) and total lesion fraction (TLF)
13. Deep transformer-based personalized dosimetry from SPECT/CT images: a hybrid approach for [177Lu]Lu-DOTATATE radiopharmaceutical therapy.
14. Quantitative SPECT (QSPECT) at high count rates with contemporary SPECT/CT systems
15. Early anterior cingulate involvement is seen in presymptomatic MAPT P301L mutation carriers
16. Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8–10 Prostate Cancers Identifies Very High–risk Patients for Early Recurrence and Resistance to Castration
17. GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome
18. Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours
19. Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC).
20. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
21. Impact of dead time on quantitative 177Lu-SPECT (QSPECT) and kidney dosimetry during PRRT
22. Comprehensive SPECT/CT system characterization and calibration for 177Lu quantitative SPECT (QSPECT) with dead-time correction
23. A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours.
24. Accuracy of 177Lu activity quantification in SPECT imaging: a phantom study
25. A CZT-based blood counter for quantitative molecular imaging
26. Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT
27. Differential Detection of Hepatic Metastases on 68Ga-DOTATATE PET/CT and 177Lu-DOTATATE SPECT/CT
28. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study
29. Nuclear Pharmacy Training in the Era of Theranostics: Toward Meeting the Needs of Nuclear Medicine Patients for Comprehensive Pharmaceutical Care.
30. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy
31. Determination of gamma camera calibration factors for quantitation of therapeutic radioisotopes
32. CCTG PR21: A randomized phase II study of [177lu]lu-PSMA-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and PSMA-positive disease (NCT04663997).
33. Impact of the dead-time correction method on quantitative 177Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy
34. Additional file 1 of Impact of the dead-time correction method on quantitative 177Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy
35. Differential Detection of Hepatic Metastases on 68 Ga-DOTATATE PET/CT and 177 Lu-DOTATATE SPECT/CT.
36. Harmonization of nomenclature for molecular imaging metrics of tumour burden: molecular tumour volume (MTV), total lesion activity (TLA) and total lesion fraction (TLF)
37. The Triple‐Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol
38. Optimizing the Schedule of PARP Inhibitors in Combination with 177Lu-DOTATATE: A Dosimetry Rationale
39. Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion
40. PSMA Theranostics: Current Landscape and Future Outlook
41. Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With 177Lu-DOTATATE: A Case Report
42. Additional file 1 of Quantitative SPECT (QSPECT) at high count rates with contemporary SPECT/CT systems
43. The Triple‐Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
44. Impact of the dead-time correction method on quantitative 177Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy.
45. The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy
46. A Dual Radiologic Contrast Agent Protocol for 18F-FDG and 18F-FLT PET/CT Imaging of Mice Bearing Abdominal Tumors
47. High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications
48. [18F]Fluorinated estradiol derivatives for oestrogen receptor imaging: impact of substituents, formulation and specific activity on the biodistribution in breast tumour-bearing mice
49. 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy
50. Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of 177Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.